‘Trelegy 200 Ellipta’ concludes negotiations with the NHIS

GSK's triple combination therapy for COPD

A triple combination therapy is set to become available in the reimbursement market, following Kolon’s Trimbow

‘Trelegy 200 Ellipta Inhaler,’ a COPD triple combination therapy, has completed the negotiations with the NHIS in Korea.

 

‘Trelegy 200 Ellipta Inhaler,’ a triple combination therapy for COPD, has completed the negotiations with the National Health Insurance Service (NHIS).

 

The drug is expected to be listed for health insurance reimbursement soon.

 

According to industry experts on the 13th, ‘Trelegy 200 Ellipta Inhaler,’ a COPD triple combination therapy, has completed the negotiations with the NHIS and is expected to be listed for reimbursement after the final reporting to the Health Insurance Policy Review Committee.

 

This drug has a unique feature of doubling the dosage of GSKs first triple combination therapy Trelegy Ellipta (ICS/LABA/LAMA).

 

‘Trelegy 200 Ellipta’ is used as a maintenance therapy for adults with asthma when the combination of long-acting beta2-adrenergic agonist and inhaled corticosteroid therapy is not providing adequate control.

 

It contains three ingredients: fluticasone furoate, umeclidinium, and vilanterol.

 

A combination of three ingredients provides enhanced therapeutic effects compared to existing drugs.

 

The inclusion of LAMA in a drug combination is anticipated to help patients with asthma that is not adequately controlled with double therapy of ICS/LABA.

 

When Trelegy 200 Ellipta is listed for reimbursement, the market for COPD triple combination therapy will become even more competitive.

 

In January, Kolon Pharmaceutical released Trimbow (beclomethasone dipropionate plus formoterol fumarate hydrate plus glycopyrronium bromide), a single inhaler triple combination therapy.

 

Clinical trials have shown that Trimbow has significant treatment effects by reducing exacerbations of moderate to severe symptoms, improving respiratory function, and enhancing the quality of life.

 

Furthermore, Trimbow has been shown to improve respiratory function and reduce exacerbations of moderate to severe symptoms in patients with asthma.

 

These results demonstrate that Trimbow is effective in managing symptoms and has a good safety profile in patients with COPD or asthma.

 

Trimbow is advantageous for patients with small airway problems because its extra-fine particles can penetrate small airways.

 

Trelegy 200 Ellipta passed the Drug Reimbursement Committee of the Health Insurance Review and Assessment Service (HIRA) last November.

 

Afterwards, it was under negotiations with the NHIS.